CN106749211B - 一种烟酸酯及其制备方法与应用 - Google Patents
一种烟酸酯及其制备方法与应用 Download PDFInfo
- Publication number
- CN106749211B CN106749211B CN201611031603.3A CN201611031603A CN106749211B CN 106749211 B CN106749211 B CN 106749211B CN 201611031603 A CN201611031603 A CN 201611031603A CN 106749211 B CN106749211 B CN 106749211B
- Authority
- CN
- China
- Prior art keywords
- nicotinate
- dimethyl
- acetenyl
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 36
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- -1 2,3- dihydroxypropyl Chemical group 0.000 claims abstract description 12
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims abstract description 8
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 238000006482 condensation reaction Methods 0.000 claims abstract description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000007858 starting material Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract description 2
- 102000005962 receptors Human genes 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 abstract description 2
- 102000003702 retinoic acid receptors Human genes 0.000 abstract description 2
- 108090000064 retinoic acid receptors Proteins 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 238000010189 synthetic method Methods 0.000 abstract description 2
- 229960001727 tretinoin Drugs 0.000 abstract description 2
- 239000011347 resin Substances 0.000 abstract 3
- 229920005989 resin Polymers 0.000 abstract 3
- 238000009776 industrial production Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102100033888 Actin-related protein 2/3 complex subunit 4 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 101000925566 Homo sapiens Actin-related protein 2/3 complex subunit 4 Proteins 0.000 description 2
- 101150026829 JUNB gene Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960005436 inositol nicotinate Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010061159 Foot deformity Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000014230 psoriasis 6 Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000034234 susceptibility to psoriasis 6 Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
本发明涉及一种烟酸脂及其制备方法与应用，该化合物为2,3‑二羟丙基‑6‑(4,4’‑二甲基‑二氢苯并噻喃基‑6‑乙炔基)烟酸脂，以6‑(4,4‘‑二甲基‑二氢苯并噻喃基‑6‑乙炔基)烟酸应用二环己基碳二亚胺(DCC)与2,3‑二羟丙醇进行缩合反应得到；是制备选择性结合二种维A酸受体(RAR‑β；RAR‑γ)，但不与维A酸X受体(RXR)结合的药物的重要中间体，是预防和治疗银屑病性关节炎,关节病性银屑病,银屑病关节炎药物的关键组成部分；其制备方法原料便宜易得，合成方法简单，是一种合成烟酸脂的全新方法，适合规模化工业生产的需要。
Description
技术领域
本发明涉及化合物生产领域，尤其是一种烟酸酯及其制备方法与应用。
背景技术
烟酸酯现阶段主要有甘露醇烟酸酯和肌醇烟酸酯。
甘露醇烟酸酯主要具有扩张血管与降低血脂作用，对降低舒张压效果明显。肌醇烟酸酯具有降低胆固醇及扩张末梢血管作用，用于高胆固醇血症及动脉粥样硬化症。
发明内容
本发明所要解决的技术问题在于提供一种烟酸酯。
本发明所要解决的另一技术问题在于提供上述烟酸酯的制备方法。
本发明所要解决的另一技术问题在于提供上述烟酸酯的应用。
为解决上述技术问题，本发明的技术方案是：
一种烟酸酯，2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯，其结构式为(Ⅰ)所示，
优选的，上述烟酸酯，2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯的核磁共振氢谱数据为1.314(S，6H)，1.930-1.915(d,2H),3.043-3.014(t,2H),3.732-3.713(d,1H),3.789-3.784(d,1H),4.116(s,1H),4.434-4.428(s,2H)，7.063-7.043(d,1H),7.260-7.215(t,1H),7.529-7.508(d,1H),7.592(s,1H),8.234-8.213(d,1H),9.140(s,1H)。
上述烟酸酯的制备方法，以6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸为起始原料，通过1步反应得到目标化合物，具体步骤如下：6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸应用二环己基碳二亚胺(DCC)与2,3-二羟丙醇进行缩合反应得到2,3-二羟丙基-6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯。
上述烟酸酯的制备方法的具体反应方程式如下：
上述烟酸酯在制备预防和治疗银屑病性关节炎的药物方面的应用。
本发明的有益效果是：
上述烟酸酯2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯是制备选择性结合二种维A酸受体(RAR-β；RAR-γ)，但不与维A酸X受体(RXR)结合的药物的重要中间体，是预防和治疗银屑病性关节炎,关节病性银屑病,银屑病关节炎药物的关键组成部分；其制备方法原料便宜易得，合成方法简单，是一种合成烟酸酯的全新方法，适合规模化工业生产的需要。
附图说明
图1为2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯的HNMR谱图。其氢谱数据为：1.314(S，6H)，1.930-1.915(d,2H),3.043-3.014(t,2H),3.732-3.713(d,1H),3.789-3.784(d,1H),4.116(s,1H),4.434-4.428(s,2H)，7.063-7.043(d,1H),7.260-7.215(t,1H),7.529-7.508(d,1H),7.592(s,1H),8.234-8.213(d,1H),9.140(s,1H)。
具体实施方式
为了使本领域的技术人员更好的理解本发明的技术方案，下面结合具体实施方式对本发明所述技术方案作进一步的详细说明。
实施例1
2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯的制备方法，具体步骤如下：将化合物1(6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸)200mg，化合物2 68mg，二环己基碳二亚胺(DCC)190mg，DMAP 100mg溶解于5ml THF，反应物混合并置换三次氮气，后室温搅拌1小时。TLC检测(DCM:MeOH＝5:1)，原料有剩余，将体系直接浓缩干并刮大板(DCM:MeOH＝10:1)得到目标产物45mg淡黄色固体。如图1所示，2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯的HNMR谱图(CDCl3)，其氢谱数据为：1.930-1.903(m，1H)，2.113-2.041(m,1H),2.385-2.299(m,4H),3.674-3.630(t,1H),7.284-7.266(q,1H),7.346-7.343(d,1H),8.386-8.372(d,1H)。
上述具体反应方程式如下：
应用试验例
参考Zenz R,Eferl R,Kenner L,et al.Psoriasis2like skin disease andarthritis caused by inducible epidermal deletion of Jun proteins[J].Nat.2005,437:369–375方法建立小鼠银屑病动物模型。选择位于PSORS6的JunB基因,通过基因敲除并联合药物干扰制备银屑病动物模型，联合敲除JunB和c2Jun基因后再给予他莫昔芬处理,18d后受试小鼠全身均出现特征性皮肤改变,在毛发稀疏的部位(耳朵、脚掌、尾巴)症状尤其明显,且该模型可见明显足部畸形、掌趾关节处炎性细胞浸润、骨组织破坏等银屑病样关节炎改变,与人类银屑病颇为相似。
将实施例1中目标化合物以0.2mg/kg剂量对20只模型小鼠肌肉注射3天，采用PsARC标准进行初次评价；而后0.4mg/kg剂量继续肌肉注射3天，采用ARC20标准进行二次评价。结果显示：PsARC有效率为65％，ARC20有效率为45％。
上述参照具体实施方式对该一种烟酸酯及其制备方法与应用进行的详细描述，是说明性的而不是限定性的，可按照所限定范围列举出若干个实施例，因此在不脱离本发明总体构思下的变化和修改，应属本发明的保护范围之内。
Claims (2)
1.一种烟酸酯在制备预防和治疗银屑病性关节炎的药物方面的应用，其特征在于：所述烟酸酯为2,3-二羟丙基-6-(4,4’-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯，其结构式为(Ⅰ)所示，
2.权利要求1中所述烟酸酯的制备方法，其特征在于：以6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸为起始原料，通过1步反应得到目标化合物，具体步骤如下：6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸应用二环己基碳二亚胺(DCC)与2,3-二羟丙醇进行缩合反应得到2,3-二羟丙基-6-(4,4‘-二甲基-二氢苯并噻喃基-6-乙炔基)烟酸酯。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611031603.3A CN106749211B (zh) | 2016-11-22 | 2016-11-22 | 一种烟酸酯及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611031603.3A CN106749211B (zh) | 2016-11-22 | 2016-11-22 | 一种烟酸酯及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106749211A CN106749211A (zh) | 2017-05-31 |
| CN106749211B true CN106749211B (zh) | 2019-08-09 |
Family
ID=58970662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611031603.3A Active CN106749211B (zh) | 2016-11-22 | 2016-11-22 | 一种烟酸酯及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106749211B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88101424A (zh) * | 1987-03-20 | 1988-10-05 | 阿勒根公司 | 具有类视网膜活性和含有杂芳香族和杂二环基团的取代乙炔及制备方法 |
| CN1674921A (zh) * | 2002-06-20 | 2005-09-28 | 爱森皮肤医学股份有限公司 | 多羟基烷烃的脂肪酸酯和吡啶羧基衍生物的新型复合物 |
| WO2016046456A1 (fr) * | 2014-09-24 | 2016-03-31 | Greenpharma | Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines chimiokines |
-
2016
- 2016-11-22 CN CN201611031603.3A patent/CN106749211B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88101424A (zh) * | 1987-03-20 | 1988-10-05 | 阿勒根公司 | 具有类视网膜活性和含有杂芳香族和杂二环基团的取代乙炔及制备方法 |
| CN1674921A (zh) * | 2002-06-20 | 2005-09-28 | 爱森皮肤医学股份有限公司 | 多羟基烷烃的脂肪酸酯和吡啶羧基衍生物的新型复合物 |
| WO2016046456A1 (fr) * | 2014-09-24 | 2016-03-31 | Greenpharma | Utilisation dermocosmetique ou pharmaceutique d'une composition contenant au moins un inhibiteur de certaines chimiokines |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106749211A (zh) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100439370C (zh) | 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤 | |
| WO2006129623A1 (ja) | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 | |
| HRP20050083A2 (en) | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs | |
| Gemma et al. | Synthesis of dihydroplakortin, 6-epi-dihydroplakortin, and their C10-desethyl analogues | |
| Erdeljac et al. | Exploring physicochemical space via a bioisostere of the trifluoromethyl and ethyl groups (BITE): attenuating lipophilicity in fluorinated analogues of Gilenya® for multiple sclerosis | |
| Bhilare et al. | Pd/PTABS: Low temperature etherification of chloroheteroarenes | |
| CN104860993B (zh) | 一种黄酮化合物前药及其用途 | |
| CN1481360A (zh) | 蕈毒碱拮抗剂 | |
| Navarrete-Vázquez et al. | Synthesis of 2-{2-[(α/β-naphthalen-1-ylsulfonyl) amino]-1, 3-thiazol-4-yl} acetamides with 11β-hydroxysteroid dehydrogenase inhibition and in combo antidiabetic activities | |
| CN106749211B (zh) | 一种烟酸酯及其制备方法与应用 | |
| JP2022068197A (ja) | デュアルｍａｇｌ及びｆａａｈインヒビター | |
| CN109369436A (zh) | 一种酰胺取代一枝蒿酮酸衍生物及制备方法和用途 | |
| Pan et al. | Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor | |
| Bernard et al. | Azoles. 17. Beta-(4-pyrazol) acrylic and propionic acids and their anti-inflammatory activity | |
| CN104781241A (zh) | 结晶化合物 | |
| CN106854204B (zh) | 一种烟酸脂化合物及其制备方法与应用 | |
| CN106749210B (zh) | 一种烟酸酯类化合物及其制备方法与应用 | |
| CN103788010B (zh) | 非布索坦中间体及其制备方法 | |
| Li et al. | Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold | |
| CH640524A5 (de) | Verfahren zur herstellung neuer benzopyranderivate. | |
| CN101490006B (zh) | 作为香草素-1受体调节剂的联芳基甲酸芳基酰胺 | |
| DelMonte et al. | Kilogram Synthesis of a Second-Generation LFA-1/ICAM Inhibitor | |
| Xu et al. | Alkenyl Thioetherification Enabled by Nickel Catalysis | |
| CN104918620B (zh) | 作为二酰基甘油酰基转移酶抑制剂的化合物 | |
| CN110483403A (zh) | 一种5-溴-4-甲氧基-1h-吲唑的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tan Wenfei Inventor after: Yao Qingjia Inventor after: Wu Simin Inventor after: Xu Yangjun Inventor before: Yao Qingjia Inventor before: Wu Simin Inventor before: Xu Yangjun |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A nicotinic acid ester and its preparation and Application Effective date of registration: 20201026 Granted publication date: 20190809 Pledgee: Tianjin SME Credit Financing Guarantee Center Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) Co.,Ltd. Registration number: Y2020120000021 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20190809 Pledgee: Tianjin SME Credit Financing Guarantee Center Pledgor: SPHINX SCIENTIFIC LABORATORY (TIANJIN) CO.,LTD. Registration number: Y2020120000021 |